Abstract

BackgroundIn 2010, the International Task Force on Canine Atopic Dermatitis (now International Committee on Allergic Diseases of Animals, ICADA) published the first consensus guidelines for the treatment of atopic dermatitis (AD) in dogs. This is the first 5-year minor update of this document.ResultsThe treatment of acute flares of AD should involve the search for, and then elimination of, the cause of the flares, bathing with mild shampoos, and controlling pruritus and skin lesions with interventions that include topical and/or oral glucocorticoids or oclacitinib. For chronic canine AD, the first steps in management are the identification and avoidance of flare factors, as well as ensuring that there is adequate skin and coat hygiene and care; this might include more frequent bathing and possibly increasing essential fatty acid intake. The medications currently most effective in reducing chronic pruritus and skin lesions are topical and oral glucocorticoids, oral ciclosporin, oral oclacitinib, and, where available, injectable recombinant interferons. Allergen-specific immunotherapy and proactive intermittent topical glucocorticoid applications are the only interventions likely to prevent or delay the recurrence of flares of AD.ConclusionsThis first 5-year minor update of the international consensus guidelines for treatment of AD in dogs further establishes that the treatment of this disease is multifaceted, and that interventions should be combined for a proven (or likely) optimal benefit. Importantly, treatment plans are likely to vary between dogs and, for the same dog, between times when the disease is at different stages.Electronic supplementary materialThe online version of this article (doi:10.1186/s12917-015-0514-6) contains supplementary material, which is available to authorized users.

Highlights

  • In 2010, the International Task Force on Canine Atopic Dermatitis ( International Committee on Allergic Diseases of Animals, ICADA) published the first consensus guidelines for the treatment of atopic dermatitis (AD) in dogs

  • 3) As in the first version of these guidelines, when recommendations are made for an intervention supported by one or more trials done with a specific product, we mention the generic drug name followed by the brand and company indicated in the paper reporting the study results

  • As most signs of canine AD are expected to respond to oral glucocorticoids or oclacitinib, clinicians should reconsider alternative diagnoses and/or the presence of secondary complications if there is no rapid clinical benefit after treating atopic dogs with these drugs (SOR C)

Read more

Summary

Results

The treatment of acute flares of AD should involve the search for, and elimination of, the cause of the flares, bathing with mild shampoos, and controlling pruritus and skin lesions with interventions that include topical and/or oral glucocorticoids or oclacitinib. For chronic canine AD, the first steps in management are the identification and avoidance of flare factors, as well as ensuring that there is adequate skin and coat hygiene and care; this might include more frequent bathing and possibly increasing essential fatty acid intake. The medications currently most effective in reducing chronic pruritus and skin lesions are topical and oral glucocorticoids, oral ciclosporin, oral oclacitinib, and, where available, injectable recombinant interferons.

Conclusions
Background
Identification and avoidance of flare factors
Improvement of skin and coat hygiene and care
Reduction of pruritus and skin lesions with pharmacological agents
Implementation of proactive topical pharmacotherapy
Implementation of nonspecific immunotherapy Summary of the 2010 guidelines
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call